The Frame: The Operational Empathy Advantage

Where we decode the systems, strategies, and business mechanics of underrepresented founders.

Today’s Briefing

Surbhi Sarna chose to solve a problem nobody thinks is interesting: FDA paperwork.

Her company Collate automates the documentation that keeps life-saving treatments stuck in regulatory limbo.

Today we're breaking down why living through a problem beats studying it, and how boring problems become highly profitable opportunities.

She was 13, lying in a hospital bed, when the doctor said something that would shape the next two decades of her life.

"We found cysts on your ovaries. We don't know if they're cancerous."

Surbhi Sarna had been fainting at school and the pain was severe enough for surgery.

But the deeper pain was the one that stayed, the uncertainty.

Doctors couldn't tell a teenager whether she had cancer.

That diagnostic gap became her obsession.

Years later, Sarna founded nVision Medical to build the first device for collecting cells from fallopian tubes which is the origin point for most ovarian cancers.

She raised $17 million.

Ran three clinical trials and Navigated two first-in-class FDA clearances.

In 2018, Boston Scientific acquired nVision for $275 million. A 15x return.

But something else happened during those years.

Something she couldn't stop thinking about.

The paperwork.

Every drug and medical device company drowns in documentation.

Research records, Clinical trial data, Manufacturing compliance, Labeling requirements.

Each FDA 510(k) submission alone takes an estimated 79 hours and that's just one filing among dozens.

Sarna spent years watching brilliant scientists, people who could cure diseases format documents and cross-reference regulatory guidelines.

Why are life-science innovators spending months on paperwork rather than saving lives?

Most people shrug. That's just how it is.

Sarna saw a opportunity.

She kept thinking about paperwork.

The late nights reformatting clinical documentation, the biotech founders at YC spending 40% of their time on regulatory filings instead of building.

In January 2025, she launched Collate at the J.P. Morgan Healthcare Conference.

$30 million seed.

Valuation over $100 million.

Her pitch: use LLMs to automate the documentation that determines whether life-saving treatments reach patients in 5 years or 15.

Most founders identify problems intellectually.

Market research. Customer interviews. TAM slides.

Sarna identified hers through 79-hour filing sessions.

Through watching scientists become bureaucrats.

This is The Operational Empathy Advantage.

Stage 1: Lived Experience, Not Market Research

Sarna didn't survey medical device companies. She was one.

Three clinical trials. Two FDA clearances. Thousands of hours of documentation.

The difference between reading about a problem and living through it?

Knowing the exceptions, not just the rules.

Sarna knows which parts of a 510(k) trip people up.

Which formatting requirements waste time.

The anxiety of waiting for FDA feedback.

That's not learnable from customer interviews.

Founders with operational empathy solve problems they've lived, not heard about.

Stage 2: Pattern Recognition Across Scale

At nVision, Sarna experienced the paperwork burden once. At YC, she watched it crush founder after founder.

Biotech. Medical devices. Diagnostics.

All drowning in the same documentation.

One experience is an anecdote. Hundreds is a pattern.

Pay close attention to problems you encounter repeatedly, not just your own, but in every founder conversation.

Problems that keep appearing across industries are usually worth solving.

They're also the ones people dismiss as "just how things are."

Stage 3: Timing the Technology to the Pain

Sarna had this insight for years.

She didn't start Collate in 2019. She started in 2025.

Because the technology finally matched the pain.

LLMs can now parse regulatory guidelines, generate compliant documentation, and cross-reference clinical data.

The 79-hour filing becomes 9 hours. The scientist goes back to science.

Operational empathy tells you what to build.

Timing tells you when.

Sarna's success with Collate didn't make her a great founder.

Her inability to forget the paperwork and solve that niche problem did.

What problems have you lived through that you've dismissed as just how things are?

Not problems you've heard about.

Problems you've experienced, the work that made you think there has to be a better way before you moved on because it seemed too boring.

Those might be the most valuable problems you know.

Keep striving and prospering.

Until next Thursday,

AP